Moleculin's 'Heart-Safe' Chemo Data Poised for ASCO Spotlight

HOUSTON, TX – May 21, 2026 – In a development that could reshape treatment paradigms for some of the most aggressive cancers, Moleculin Biotech is preparing to present powerful new cardiac safety data for its lead drug candidate, Annamycin. The findings, accepted for a poster presentation at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, suggest the drug may solve a decades-old problem that has plagued a cornerstone of chemotherapy: debilitating heart damage.

For patients with acute myeloid leukemia (AML) and soft tissue sarcoma (STS), anthracyclines are a potent weapon. However, their use is limited by cumulative dose-dependent cardiotoxicity, forcing doctors and patients into a difficult trade-off between fighting the cancer and risking long-term heart failure. Moleculin’s latest data on Annamycin indicates a potential path to delivering the powerful anti-cancer effects of an anthracycline without this severe drawback, a prospect that has the oncology community watching closely.

Redefining Anthracycline Safety

The abstract, titled “Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis,” details a comprehensive review of Annamycin’s impact on the heart. The analysis pooled data from 90 patients across five separate clinical trials, creating a robust dataset independently reviewed by cardio-oncology specialists.

Key to the findings is the measurement of Left Ventricular Ejection Fraction (LVEF), a critical indicator of the heart's pumping efficiency. Across 78 patients with available pre- and post-treatment LVEF assessments, the results were striking: there was no statistically significant change in heart function. The mean difference was a negligible -0.12%, demonstrating a remarkable lack of cardiac impact.

What makes this finding particularly significant is the dosage patients received. The median cumulative dose of Annamycin was 660 mg/m², with some patients receiving as much as 2,970 mg/m². These levels often exceed the conventional lifetime limits for traditional anthracyclines, beyond which the risk of irreversible heart damage typically becomes unacceptable. Despite these high cumulative exposures, the analysis found no correlation between the total dose of Annamycin and any change in heart function. Furthermore, patient age, another common risk factor for cardiotoxicity, also showed no correlation with LVEF changes.

“Acceptance of these findings at ASCO highlights the growing body of evidence supporting the differentiated safety profile of Annamycin,” said Walter Klemp, Chairman and CEO of Moleculin, in a statement. “These data continue to support the potential for Annamycin to provide effective anthracycline therapy without the traditional cumulative dose limitations associated with cardiotoxicity.”

A Lifeline Beyond Survival

The clinical challenge posed by anthracycline cardiotoxicity cannot be overstated. For decades, it has been the Achilles' heel of an otherwise effective class of drugs. This toxicity can manifest years after treatment, impacting the quality of life for cancer survivors. The need for a safer alternative is a significant unmet medical need, particularly in relapsed or refractory AML, where patients may have already been exposed to other cardiotoxic agents.

Annamycin’s presentation at the ASCO meeting will occur within the "Symptom Science and Palliative Care" session. While seemingly a niche placement, it is highly appropriate. By potentially eliminating a severe, life-altering side effect, Annamycin's primary value proposition extends beyond mere efficacy to encompass a better quality of life for patients both during and after treatment. It represents a shift from focusing solely on survival to focusing on a patient's long-term well-being.

This is bolstered by Annamycin's design, which not only aims to be non-cardiotoxic but also to evade the multidrug resistance mechanisms that cancers often develop to survive chemotherapy. This dual mechanism could make it a vital option for heavily pre-treated patients whose cancers have stopped responding to standard therapies.

A Strategic Play in a Competitive Field

The positive safety data does more than offer hope to patients; it significantly de-risks Moleculin's development path in a fiercely competitive oncology market. The company is currently enrolling patients in its pivotal Phase 2b/3 MIRACLE trial, which evaluates Annamycin in combination with cytarabine for relapsed or refractory AML. Strong safety data provides a firmer foundation for this large, expensive trial and strengthens the drug's potential regulatory and commercial case.

The landscape for AML is crowded with innovative therapies, including targeted agents like FLT3 inhibitors (gilteritinib) and IDH inhibitors (ivosidenib), as well as the widely adopted Bcl-2 inhibitor venetoclax. However, many patients still relapse or are ineligible for these treatments. Annamycin could carve out a crucial niche as a highly effective therapy for patients who have exhausted other options, particularly those for whom further treatment with traditional anthracyclines would be too dangerous for their heart.

This potential was hinted at in a prior Phase 1b/2 study, which showed a 50% complete remission rate and a median overall survival of over 12 months in a difficult-to-treat AML population. The new safety data adds a critical layer of validation to these promising efficacy results.

The Road from Poster to Pharmacy

While a poster at ASCO is a significant milestone for validating research, the true test for Annamycin lies ahead. All eyes are on the MIRACLE trial, with the company announcing that an unblinding of interim data is imminent in mid-2026. This will be a major catalyst for Moleculin, providing the first look at randomized, controlled data from its pivotal study.

Like many clinical-stage biotech companies, Moleculin faces the challenge of funding these extensive trials. Although its balance sheet shows more cash than debt, the company has acknowledged it will require significant additional financing to see its programs through to completion. The strong data presented at ASCO could be instrumental in securing that future funding.

Beyond Annamycin for AML and STS, Moleculin is also developing other candidates, including WP1066 for brain tumors and WP1122 for viruses and cancers. However, Annamycin is unequivocally the company's lead asset. Its journey from a promising molecule to a potential new standard of care now hinges on translating this exceptional safety profile into definitive proof of efficacy in its ongoing pivotal trial.